PT-141 has been studied for distressing low desire, with modest average changes in certain women before menopause. It hasn't been shown to work for everyone. Most PT-141 myths make a narrow finding sound like a much bigger promise.
PT-141 is another name for bremelanotide, the molecule in Vyleesi. A compounded preparation is made by a pharmacy for an individual prescription; it isn't the same finished product. Keeping the molecule, the brand, and the pharmacy preparation separate makes these claims easier to check.
PT-141 myths: what the grades mean
Supported means the claim matches the evidence. Partly means a piece holds up. Not supported means the claim goes beyond the findings. Unknown means the evidence hasn't settled the question either way.
1. “It's an aphrodisiac that works for anyone.”
Not supported: an aphrodisiac is meant to increase desire, but the studies didn't show a benefit for everyone. RECONNECT studied women before menopause with acquired, generalized hypoactive sexual desire disorder, or HSDD: distressing low desire that developed after normal desire and occurs across situations. Another condition, medicine, or relationship problem couldn't explain it. Kingsberg and colleagues, Obstetrics & Gynecology, 2019, reported average improvements in desire and distress; the PT-141 clinical-trials guide explains those findings and their limits.
2. “It's proven for men.”
Partly: Diamond's 2004 study and Rosen's 2004 study, both in International Journal of Impotence Research, recorded erectile responses in men. Those short experiments measured erections in healthy men and in men with erectile dysfunction, not low desire, and they don't establish a dependable treatment; Vyleesi's label says it is “not indicated for the treatment of HSDD in postmenopausal women or in men.” A larger 2008 men's trial carries a 2023 expression of concern, a journal notice questioning the paper; a separate 2008 women's trial is retracted, meaning withdrawn from the scientific record. The evidence for PT-141 in men needs those qualifications attached.
3. “It works like Viagra.”
Not supported: Viagra's label describes sildenafil helping blood flow into the penis during sexual stimulation. Bremelanotide activates melanocortin receptors, docking points on cells involved in several body signals, including sexual response. The Vyleesi prescribing information, marked “Revised: 3/2024,” says exactly how it improves HSDD remains unknown. A different target means it isn't a stronger Viagra or a stand-in for one, and Vyleesi's label says it is “not indicated to enhance sexual performance.”
4. “PT-141 and Vyleesi are the same product.”
Partly: PT-141 and bremelanotide name the same molecule, and Vyleesi contains bremelanotide. PT-141 prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product such as Vyleesi: the formulation offered here is not FDA-approved. As FDA explains, it doesn't verify compounded drugs' safety, effectiveness, or quality before marketing; the brand's review doesn't establish identical results for another finished preparation.
5. “It dangerously raises everyone's blood pressure.”
Partly: a temporary rise is real; the same dangerous outcome for everyone isn't established. White and colleagues, Journal of Hypertension, 2017, found small, temporary average increases in 397 premenopausal women whose blood pressure was normal or controlled. The Vyleesi label says it “transiently increases blood pressure”; readings usually return to starting levels within 12 hours. It rules out uncontrolled high blood pressure and known heart or blood-vessel disease; a small average doesn't clear an individual for treatment, as the blood-pressure guide explains.
6. “It's fine to use every day.”
Not supported: daily use isn't Vyleesi's labeled routine. Section 2.1 limits the branded medicine to one dose within 24 hours and says, “More than 8 doses per month is not recommended.” Closer dosing may add blood-pressure effects, and in one study the label describes, 38% of people given Vyleesi daily for 8 days developed patches of darker skin; more frequent use also lengthens the time each month that blood pressure is raised. Those are label facts about Vyleesi, not a schedule for a compounded prescription; the prescriber sets the actual dose and timing.
7. “Nausea means it's working.”
Not supported: nausea was a side effect, not RECONNECT's measure of benefit. About 2 in 5 women receiving bremelanotide reported nausea, versus roughly 1 in 100 receiving placebo, an inactive comparison treatment: 40.0% versus 1.3%. Those figures come from the 2019 RECONNECT paper. The researchers measured benefit through desire and distress questionnaires; feeling sick isn't evidence that those outcomes improved, and feeling well isn't evidence that treatment failed.
8. “It's a tanning peptide.”
Partly: its family history runs through tanning research, as Hadley and Dorr explained in Peptides, 2006. But bremelanotide and the related molecule melanotan II aren't identical. Vyleesi's label warns about focal hyperpigmentation, meaning patches of darker skin, including on the face, gums, or breasts. Some patches weren't confirmed to fade after treatment stopped; that unwanted change is a side effect, not evidence that PT-141 is a suitable tanning treatment.
9. “It works after menopause.”
Unknown: Vyleesi's label says it is “not indicated” for women after menopause. An earlier nasal trial, a phase 2 study of postmenopausal women with arousal disorder completed in 2007, did enroll that population, though its registry record posts no results; outside the indication doesn't mean never studied. As of October 29, 2026, the day this article was written, the VA/DoD menopause guideline dated August 2026 excludes bremelanotide from its review because its indication covers women before menopause. Neither that exclusion nor the earlier trial establishes benefit from today's compounded preparations.
10. “Alcohol doesn't matter.”
Partly: a 2017 alcohol-interaction study by Clayton and colleagues in Clinical Therapeutics found no meaningful interaction in how alcohol and bremelanotide moved through the body. It involved just 24 healthy adults and an older nasal preparation, rather than today's branded injection. That limited experiment isn't blanket reassurance about every drinking pattern, health history, or compounded prescription. The separate PT-141 and alcohol guide covers that narrower question.
What a prescription adds to the evidence
As of October 29, 2026, the day this article was written, an FDA letter dated August 24, 2026 names an online seller's PT-141 among unapproved new drugs. The letter addresses that seller's products and marketing. A prescribed route adds a reviewing clinician, a licensed U.S. compounding pharmacy, dispensing records, and a contact for problems.
A licensed provider may still prescribe — that decision is between you and your doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies. The review connects the person's symptoms, blood pressure, heart history, and medicines with the evidence above, rather than treating a familiar peptide name as a complete treatment plan.
